Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L&J-DM
- Development stage
- Preclinical
- Lead developer
- L&J Bio
- Modality
- Peptides
- Administration
- Oral
01
Overview
L&J-DM is a bio-better biologic candidate being developed by L&J Bio for the treatment of diabetes mellitus. The drug is part of L&J Bio's pipeline of oral formulations of previously injectable biologics, utilizing their proprietary platform technology designed to convert protein and peptide drugs into oral dosage forms to improve patient compliance and therapeutic efficacy. While the specific molecular target of L&J-DM has not been explicitly disclosed by the developer, it is categorized as a bio-better, indicating it is an optimized version of an existing biological therapy for diabetes. The candidate is currently in the early stages of development.
Beyond the preview
Go deeper on L&J-DM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L&J-DM.